HCW Biologics (NASDAQ: HCWB) files amended Q2 2025 8-K/A

Rhea-AI Filing Summary

HCW Biologics Inc. filed an amended Form 8-K/A to correct a clerical error about the timing of a press release. The amendment explains that the press release announcing financial results was issued on August 18, 2025 instead of August 14, 2025, as originally indicated.

The company states that no other disclosures from the original report are being updated and that the amendment should be read together with the original filing and later SEC filings. The press release for the quarter ended June 30, 2025 is furnished as Exhibit 99.1, not deemed “filed” under the Exchange Act.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

true000182867300018286732025-08-142025-08-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2025

HCW Biologics Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40591	82-5024477
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
2929 N. Commerce Parkway
Miramar, Florida				33025
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 954 842-2024

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		HCWB		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Explanatory Note

The Company is filing this Amendment No. 1 on Form 8K/A (the “Amendment”) to the Current Report on Form 8-K filed with the Securities and Exchange Commission (“SEC”) on August 14, 2025 (“Original Form 8-K”) due to a clerical error with respect to a delay in issuance of the press release included as Exhibit 99.1 from August 14, 2025 to August 18, 2025.

Except as stated herein, this Current Report on Form 8-K/A does not reflect events occurring after the filing of the Original Form 8-K on August 14, 2024 and no attempt has been made to this Current Report on Form 8-K/A to modify or update other disclosures as presented in the Original Form 8-K. Accordingly, this Form 8-K/A should be read in conjunction with the Original Form 8-K and our filings with the SEC subsequent to the filing of the Original Form 8-K.
 

Item 2.02 Results of Operations and Financial Condition.

On August 18, 2025, HCW Biologics Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information set forth in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release dated August 18, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			HCW BIOLOGICS INC.
Date:	August 18, 2025	By:	/s/ Hing C. Wong
			Hing C. Wong Founder and Chief Executive Officer

FAQ

What is HCW Biologics (HCWB) Form 8-K/A about?

The Form 8-K/A from HCW Biologics Inc. corrects a clerical error related to the stated issuance date of a press release. It clarifies that the financial results press release was issued on August 18, 2025, and does not change any other prior disclosures.

Why did HCW Biologics (HCWB) amend its original 8-K?

HCW Biologics amended its original 8-K to fix an incorrect press release date. The amendment notes a delay in issuing the press release from August 14, 2025 to August 18, 2025, while confirming that all other information from the original report remains unchanged.

What financial period does HCW Biologics (HCWB) discuss in the 8-K/A?

The amendment states that HCW Biologics issued a press release announcing financial results for the quarter ended June 30, 2025. The detailed results are contained in Exhibit 99.1, which is furnished with the report but not incorporated as filed financial statements.

How is Exhibit 99.1 treated in HCW Biologics (HCWB) 8-K/A?

Exhibit 99.1 is the press release dated August 18, 2025, announcing quarterly results. The company specifies that this exhibit, and the related Item 2.02 information, is being furnished rather than filed, so it is not subject to Section 18 liability or automatic incorporation by reference.

Does HCW Biologics (HCWB) 8-K/A update events after the original filing?

The amendment explicitly says it does not reflect events occurring after the original 8-K filing. It focuses solely on correcting the press release timing, and instructs readers to review the original report and subsequent SEC filings for any later developments.

Who signed the HCW Biologics (HCWB) Form 8-K/A?

The Form 8-K/A was signed on behalf of HCW Biologics Inc. by Hing C. Wong, the company’s Founder and Chief Executive Officer, dated August 18, 2025. This signature confirms the amendment was duly authorized under the Securities Exchange Act of 1934.